Brandt-Christensen M, Kvist K, Nilsson F M, Andersen P K, Kessing L V
Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark.
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):781-3. doi: 10.1136/jnnp.2005.083345.
To estimate the risk for persons treated with antidepressants or lithium of subsequent treatment with antiparkinson drugs (APD).
The Danish national prescription database supplied data on all persons who received antidepressants, lithium, or antidiabetics (first control group). A second control group was included comprising persons from the general population. Outcome was purchase of APD and the study period was 1995 to 1999.
In total, 1 293 789 persons were included. The rate ratio of treatment with APD after treatment with antidepressants was 2.27 (95% CI 2.14 to 2.42) for men and 1.50 (95% CI 1.43 to 1.58) for women. Figures for lithium were almost identical.
Persons treated with antidepressants or lithium are at increased risk of subsequently treatment with APD, showing an association between anxiety/affective disorder and Parkinson's disease.
评估接受抗抑郁药或锂盐治疗的患者随后使用抗帕金森药物（APD）治疗的风险。
丹麦国家处方数据库提供了所有接受抗抑郁药、锂盐或抗糖尿病药物治疗的患者的数据（第一对照组）。第二对照组包括来自普通人群的个体。观察指标为APD的购买情况，研究时间段为1995年至1999年。
总共纳入了1293789人。男性在接受抗抑郁药治疗后使用APD的治疗率比为2.27（95%可信区间2.14至2.42），女性为1.50（95%可信区间1.43至1.58）。锂盐治疗后的数字几乎相同。
接受抗抑郁药或锂盐治疗的患者随后使用APD的风险增加，表明焦虑/情感障碍与帕金森病之间存在关联。
